CervoMed Inc. Files 8-K
Ticker: CRVO · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-actions, filing
TL;DR
CervoMed Inc. filed an 8-K on Nov 4, 2024. Old name was Diffusion Pharmaceuticals.
AI Summary
CervoMed Inc. filed an 8-K on November 4, 2024, reporting other events and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing provides an update on CervoMed Inc.'s corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating no immediate significant events or changes.
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former company name
- RestorGenex Corp (company) — Former company name
- Stratus Media Group, Inc (company) — Former company name
- November 4, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for CervoMed Inc.?
The filing is for 'Other Events' and 'Financial Statements and Exhibits' as of November 4, 2024.
When was CervoMed Inc. incorporated and where is it headquartered?
CervoMed Inc. is incorporated in Delaware and headquartered at 20 Park Plaza, Suite 424, Boston, MA.
What were some of CervoMed Inc.'s previous names?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc.
What is CervoMed Inc.'s IRS Employer Identification Number?
CervoMed Inc.'s IRS Employer Identification Number is 30-0645032.
What is the SEC file number for CervoMed Inc.?
The SEC file number for CervoMed Inc. is 001-37942.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-11-04 17:29:31
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20241104_8k.htm (8-K) — 27KB
- ex_742707.htm (EX-99.1) — 20KB
- logosm.jpg (GRAPHIC) — 7KB
- 0001437749-24-033168.txt ( ) — 192KB
- crvo-20241104.xsd (EX-101.SCH) — 3KB
- crvo-20241104_def.xml (EX-101.DEF) — 11KB
- crvo-20241104_lab.xml (EX-101.LAB) — 15KB
- crvo-20241104_pre.xml (EX-101.PRE) — 11KB
- crvo20241104_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events On November 4, 2024, CervoMed Inc. issued a press release announcing key takeaways from two oral presentations characterizing the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies that were presented at the Clinical Trials on Alzheimer's Disease Conference. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued November 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 4, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel